Last updated: March 8, 2026
What is NDC 00378-3001?
NDC 00378-3001 corresponds to a specific pharmaceutical product registered with the National Drug Code (NDC) system. Based on available data, it is identified as Rituximab (trade name: Rituxan), used primarily for treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Note: Confirm the exact product details from FDA or manufacturer sources to verify chemical composition and formulation.
Market Overview
Product Class and Therapeutic Area
- Drug class: Monoclonal antibody (mAb)
- Therapeutic areas: Oncology, autoimmune disorders
- Market size (2022): Estimated global market at approximately $10.4 billion [1]
- Key competitors: Concurrent products include Obinutuzumab (Gazyva), Ofatumumab, and biosimilars
Key Market Drivers
- Rise in incidence of lymphoma and autoimmune diseases
- Increasing adoption of biologics in oncology
- Patent expiration of originator biologics leading to biosimilar entry
- Growing approval of biosimilars for Rituximab
Regulatory Environment
- U.S. FDA-approved since 1997
- Several biosimilars approved in the U.S. (e.g., Truxima, Ruxience, Riabni)
- European Medicines Agency (EMA) approved biosimilars since 2017
Production and Supply Chain Considerations
- Manufacturing involves complex cell culture processes
- Market dynamics affected by biosimilar proliferation
- Patent litigations and expirations influence pricing strategies
Price Trends and Projections
Current Pricing Landscape
- Brand-name Rituxan wholesale acquisition cost (WAC): approximately $4,731 per 100 mg vial (as of 2023)
- Biosimilar prices: 15-30% lower than the originator
- Average patient out-of-pocket costs vary depending on insurance coverage
Price Drivers
- Biosimilar Competition: Entry of biosimilars reduces prices
- Contract Negotiations: Payers leverage biosimilar options for discounts
- Manufacturing Cost Trends: Technological improvements can lower costs over time
Price Projections (2023-2028)
| Year |
Estimated WAC for Biosimilars |
Expected Price Reduction (%) |
Rationale |
| 2023 |
$3,500 - $4,000 per 100 mg |
baseline |
Biosimilar competition begins to impact pricing |
| 2024 |
$3,200 - $3,800 |
10-15% |
Increased biosimilar market penetration |
| 2025 |
$2,900 - $3,500 |
15-20% |
More biosimilar approvals expand market share |
| 2026 |
$2,700 - $3,200 |
20-25% |
Cost efficiencies improve manufacturing processes |
| 2027 |
$2,500 - $3,000 |
20-30% |
Market saturation with biosimilars enhances price pressure |
| 2028 |
$2,300 - $2,800 |
25-30% |
Competitive dynamics favor aggressive pricing |
Note: Prices refer to wholesale acquisition costs (WAC). Actual patient net prices vary based on negotiations and insurance.
Market Shifts Impacting Price and Adoption
- Biosimilar Approval Rates: Accelerated approvals (e.g., Truxima approved in 2018) contribute to downward pricing trends.
- Physician Adoption: Prescribing patterns pivot on biosimilar confidence, influencing volume and pricing.
- Reimbursement Policies: CMS and private insurers favor biosimilars, pressuring originator prices.
Strategic Insights for Stakeholders
- Pharmaceutical Companies: Focus on biosimilar development, cost containment, and market share expansion.
- Investors: Monitor biosimilar pipeline and patent cliff timelines to anticipate pricing dynamics.
- Healthcare Providers: Optimize formulary decisions based on evolving cost structures.
Key Takeaways
- NDC 00378-3001, identified as Rituximab, faces increasing biosimilar competition.
- Market size exceeds $10 billion globally, with growth driven by autoimmune and cancer indications.
- Wholesale prices for biosimilars are projected to decline approximately 20-30% over five years.
- Price reductions follow patent expirations and expanded biosimilar approvals.
- Pricing strategies increasingly rely on biosimilar adoption and payer negotiations.
Frequently Asked Questions
Q1: What factors most influence Rituximab’s market price?
A1: Patent expiration, biosimilar entry, payer negotiations, and manufacturing efficiencies.
Q2: How soon can biosimilar competitors significantly reduce prices?
A2: Typically within 1-3 years of approval, depending on market acceptance and regulatory environment.
Q3: Are biosimilar prices uniform across regions?
A3: No; prices vary widely by country due to differing healthcare policies and pricing regulations.
Q4: What impact do biosimilars have on overall treatment costs?
A4: Biosimilars generally reduce treatment costs by 15-30%, improving access and affordability.
Q5: When is the patent expiry for the original Rituximab product?
A5: The primary patent expired in the U.S. in 2016, with subsequent patents and exclusivities expiring in various markets through 2025.
References
[1] EvaluatePharma. (2022). Global biologics market report.
[2] FDA. (2023). Approved biosimilars for Rituximab.
[3] IQVIA. (2022). Biologic drug pricing and market data.
[4] EMA. (2017). Biologic approvals and biosimilars.
[5] Centers for Medicare & Medicaid Services (CMS). (2023). Biosimilar reimbursement policies.
